Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST)

ADJUST

Clinicaltrials.gov ID: NCT03816397

What is the goal of the study?

Multicenter, block-randomized, double-masked, placebo-controlled trial to compare the safety and efficacy of stopping adalimumab treatment versus continuing adalimumab treatment in patients with uveitis associated with juvenile idiopathic arthritis (JIA). The primary objective is to compare time to recurrence of ocular inflammation between JIA-associated uveitis patients randomized to stop adalimumab treatment and patients randomized to continue treatment.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Kabita Nanda
Study Team Member: Nidhi Naik, Nidhi.Naik@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.